Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several claims provided are not verifiable against the supplied FDA label excerpts as given (notably exercise/activity-level and specific creatinine clearance dosing thresholds). While some pharmacokinetic/renal-elimination statements match, the response includes multiple assertions that are not supported by the provided label text, leading to poor overall alignment.
Category Scores
Accurate Statements
Pregabalin is primarily cleared by the kidneys.
Supported by label excerpt: 'LYRICA is eliminated primarily by renal excretion' (2.1 and 2.7; also 12.3).
Pregabalin elimination depends on kidney function (creatinine clearance).
Supported by label excerpt: dosing adjustments 'Base the dose adjustment... on creatinine clearance (CLcr)' (2.7) and 'elimination nearly proportional to creatinine clearance' (12.3).
Unsupported Statements
Pregabalin (Lyrica) dosing does not require adjustment solely due to increased exercise in most patients.
The provided label excerpts do not mention physical activity/exercise as a dosing adjustment factor.
Pregabalin pharmacokinetics (absorption, distribution, metabolism, and elimination) remain stable regardless of physical activity levels.
No label excerpt addresses how exercise affects pregabalin pharmacokinetics.
Intense, prolonged exercise can temporarily reduce renal blood flow or cause dehydration, potentially elevating serum creatinine and slowing pregabalin clearance in vulnerable patients.
No label excerpt supports the proposed exercise physiology or link to serum creatinine affecting pregabalin clearance.
Vulnerable patients include elderly patients or patients with baseline mild renal impairment.
The label excerpt supports that older patients may require dose adjustment due to renal impairment, but it does not define exercise-related vulnerability or mild renal impairment in this context.
Standard dosing guidelines recommend no adjustment for transient exercise effects.
Label excerpts do not mention exercise/transient exercise effects or corresponding dosing guidance.
Monitoring may be needed if chronic high-intensity training leads to persistent dehydration or acute kidney injury.
No label excerpt mentions exercise-derived dehydration or acute kidney injury as an indication for monitoring or dosing changes.
Pfizer prescribing information recommends initial doses of pregabalin 150 mg/day divided for most indications like neuropathic pain or fibromyalgia.
The provided excerpts include renal dosing and general statements, but do not include initial dosing values such as 150 mg/day or indication-specific starting doses.
Pfizer prescribing information states pregabalin can be titrated up to 600 mg/day based on response and tolerability.
The provided excerpts do not include the 600 mg/day maximum or titration limits.
Pregabalin dosing adjustments are specified for age greater than 65.
The label excerpt provided (8.5) indicates 'dose adjustment may be required due to renal impairment' but does not specify dosing adjustment rules solely based on age >65.
Pregabalin dosing adjustments are specified for drug interactions.
The provided interaction excerpt discusses additive cognitive/gross motor effects with CNS depressants and lack of pharmacokinetic interaction significance; it does not provide specific 'dose adjustment' directives for drug interactions.
Pfizer prescribing information does not list activity level as a factor for pregabalin dosing adjustment.
This is not directly supported as a negative statement from the provided excerpts.
Contradictions
Low
AI Statement
Rare cases of muscle pain and rhabdomyolysis have been noted anecdotally with high doses and extreme exertion in users of Lyrica.
Label Reference
5.11 'Creatine Kinase Elevations' supports unexplained muscle pain/tenderness/weakness and rhabdomyolysis events occurring in three subjects, but the label excerpts do not attribute this to 'extreme exertion' or 'anecdotally with high doses.' The exercise/eternity framing is therefore not a direct contradiction but is unsupported rather than contradicted.
Important Omissions
Boxed warnings (if any), detailed contraindications beyond hypersensitivity, and comprehensive warnings/precautions (e.g., suicidal behavior, respiratory depression) were not addressed by the AI claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because multiple claims about exercise-based dosing/no adjustment, specific initial/maximum doses, and interaction-based dosing adjustments are not supported by the provided label excerpts, there is potential for misapplication of dosing/monitoring guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Several key dosing/titration and exercise-physiology claims are not present in the provided label excerpts; age-based adjustment is asserted too specifically, and drug-interaction-based dose adjustment is not supported.
Suggested Improvement
Limit claims to label-supported statements in the provided excerpts (e.g., renal excretion and creatinine clearance–based dosing adjustments; dizziness/somnolence; CK/rhabdomyolysis instructions). Remove or qualify any assertions about exercise/activity effects, specific numeric starting/titration/maximum doses, and interaction-based dosing adjustments unless the exact label text is provided.